SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
SciSparc Ltd. recently announced MitoCareX Bio Ltd., the company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which resulted in the identification of several molecules that could be used for potential anti-cancer treatments.
As previously announced by the company on March 12, 2024, by using its in-vitro screening systems related to the mitochondria, MitoCareX corroborated its virtual findings by confirming the anti-cancer biological activity of several small molecule structures.
Additionally, by utilizing the extensive virtual data generated, MitoCareX is working toward creating a predictive AI model. This model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target its SLC25 protein of interest.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
Total Page Views: 530
